| language |
eng
|
| Author |
Enomoto Hiroyuki
Bio-Medicine, Medicines Development Unit, Eli Lilly Japan K.K., Kobe, Japan
Alev Levent
Bio-Medicine, Medicines Development Unit, Eli Lilly Japan K.K., Kobe, Japan
Kato Yuki
Clinical Development Department, Shionogi & Co., Ltd., Osaka, Japan
Ishihara Hiroyuki
Clinical Development Department, Shionogi & Co., Ltd., Osaka, Japan
Tsuji Toshinaga
Medical Affairs Department, Shionogi & Co., Ltd., Osaka, Japan
Ochiai Toshimitsu
Biostatistics Department, Shionogi & Co., Ltd., Osaka, Japan
Konno Shinichi
Department of Orthopaedic Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan
|
| Subject | double-blind; randomized; placebo-controlled trial; duloxetine; osteoarthritis
|
| Journal Title |
JOURNAL OF PAIN RESEARCH
|
| Volume | 11
|
| Start Page | 809
|
| End Page | 821
|
| ISSN | 1178-7090
|
| Published Date | 2018
|
| DOI | |
| PubMed ID | |
| Publisher | DOVE MEDICAL PRESS LTD
|
| NII Type |
Journal Article
|
| OAI-PMH Set |
Faculty of Medicine
|
| Remark | The authors thank all clinical investigators and patients for their participation in the study. The authors thank Marion Barnett and Nicholas Smith of Edanz Medical Writing for providing medical writing support, which was funded by Shionogi & Co., Ltd. Editing of the final manuscript was provided by Serina Stretton of ProScribe-Envision Pharma Group and funded by Shionogi & Co., Ltd.; This work was supported by Shionogi & Co., Ltd., Eli Lilly Japan K. K., and Eli Lilly and Company. Shionogi & Co., Ltd., Eli Lilly Japan K. K., and Eli Lilly and Company contributed to study design, data analysis, and writing of the manuscript.
|
